IgG-assisted Age-dependent Clearance of Alzheimer's Amyloid Beta Peptide by the Blood-brain Barrier Neonatal Fc Receptor

Overview

Journal J Neurosci

Specialty Neurology

Date 2005 Dec 16

PMID 16354907

Citations 114

Authors

Rashid Deane

Abhay Sagare

Katie Hamm

Margaret Parisi

Barbra LaRue

Huang Guo

Zhenhua Wu

David M Holtzman

Berislav V Zlokovic

Affiliations

Soon will be listed here.

Abstract

The role of blood-brain barrier (BBB) transport in clearance of amyloid beta-peptide (Abeta) by Abeta immunotherapy is not fully understood. To address this issue, we studied the effects of peripherally and centrally administered Abeta-specific IgG on BBB influx of circulating Abeta and efflux of brain-derived Abeta in APPsw(+/-) mice, a model that develops Alzheimer's disease-like amyloid pathology, and wild-type mice. Our data show that anti-Abeta IgG blocks the BBB influx of circulating Abeta in APPsw(+/-) mice and penetrates into the brain to sequester brain Abeta. In young mice, Abeta-anti-Abeta complexes were cleared from brain to blood by transcytosis across the BBB via the neonatal Fc receptor (FcRn) and the low-density lipoprotein receptor-related protein (LRP), whereas in older mice, there was an age-dependent increase in FcRn-mediated IgG-assisted Abeta BBB efflux and a decrease in LRP-mediated clearance of Abeta-anti-Abeta complexes. Inhibition of the FcRn pathway in older APPsw(+/-) mice blocked clearance of endogenous Abeta40/42 by centrally administered Abeta immunotherapy. Moreover, deletion of the FcRn gene in wild-type mice inhibited clearance of endogenous mouse Abeta40/42 by systemically administered anti-Abeta. Our data suggest that the FcRn pathway at the BBB plays a crucial role in IgG-assisted Abeta removal from the aging brain.

Citing Articles

Enhancing Antibody Exposure in the Central Nervous System: Mechanisms of Uptake, Clearance, and Strategies for Improved Brain Delivery.

Schwinghamer K, Siahaan T J Nanotheranostics. 2025; 4(4):463-479.

PMID: 39897432 PMC: 11784990. DOI: 10.3390/jnt4040020.

Blood-based therapies to combat neurodegenerative diseases.

Lee J, Lim M, Koh R, Tsen M, Chye S Metab Brain Dis. 2024; 39(5):985-1004.

PMID: 38842660 DOI: 10.1007/s11011-024-01368-x.

Taming microglia: the promise of engineered microglia in treating neurological diseases.

Luo E, Sugimura R J Neuroinflammation. 2024; 21(1):19.

PMID: 38212785 PMC: 10785527. DOI: 10.1186/s12974-024-03015-9.

Engineered serum markers for non-invasive monitoring of gene expression in the brain.

Lee S, Nouraein S, Kwon J, Huang Z, Wojick J, Xia B Nat Biotechnol. 2024; 42(11):1717-1725.

PMID: 38200117 PMC: 11233427. DOI: 10.1038/s41587-023-02087-x.

Exit pathways of therapeutic antibodies from the brain and retention strategies.

Schellhammer L, Beffinger M, Salazar U, Laman J, Buch T, Vom Berg J iScience. 2023; 26(11):108132.

PMID: 37915602 PMC: 10616392. DOI: 10.1016/j.isci.2023.108132.

References

Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T . Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999; 400(6740):173-7. DOI: 10.1038/22124. View

Bard F, Cannon C, Barbour R, Burke R, Games D, Grajeda H . Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000; 6(8):916-9. DOI: 10.1038/78682. View

Shibata M, Yamada S, Kumar S, Calero M, Bading J, Frangione B . Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest. 2000; 106(12):1489-99. PMC: 387254. DOI: 10.1172/JCI10498. View

Janus C, Pearson J, McLaurin J, Mathews P, Jiang Y, Schmidt S . A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 2001; 408(6815):979-82. DOI: 10.1038/35050110. View

Morgan D, Diamond D, Gottschall P, Ugen K, Dickey C, Hardy J . A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 2001; 408(6815):982-5. DOI: 10.1038/35050116. View

Kawarabayashi T, Younkin L, Saido T, Shoji M, Ashe K, Younkin S . Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci. 2001; 21(2):372-81. PMC: 6763819. View

Bacskai B, Kajdasz S, Christie R, Carter C, Games D, Seubert P . Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med. 2001; 7(3):369-72. DOI: 10.1038/85525. View

Ravetch J, Bolland S . IgG Fc receptors. Annu Rev Immunol. 2001; 19:275-90. DOI: 10.1146/annurev.immunol.19.1.275. View

DeMattos R, Bales K, Cummins D, Dodart J, Paul S, Holtzman D . Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2001; 98(15):8850-5. PMC: 37524. DOI: 10.1073/pnas.151261398. View

10.

Thorell J, Johansson B . Enzymatic iodination of polypeptides with 125I to high specific activity. Biochim Biophys Acta. 1971; 251(3):363-9. DOI: 10.1016/0005-2795(71)90123-1. View

11.

Sigurdsson E, Scholtzova H, Mehta P, Frangione B, Wisniewski T . Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am J Pathol. 2001; 159(2):439-47. PMC: 1850561. DOI: 10.1016/s0002-9440(10)61715-4. View

12.

Das P, Murphy M, Younkin L, Younkin S, Golde T . Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol Aging. 2001; 22(5):721-7. DOI: 10.1016/s0197-4580(01)00245-7. View

13.

DeMattos R, Bales K, Cummins D, Paul S, Holtzman D . Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science. 2002; 295(5563):2264-7. DOI: 10.1126/science.1067568. View

14.

Dodart J, Bales K, Gannon K, Greene S, DeMattos R, Mathis C . Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci. 2002; 5(5):452-7. DOI: 10.1038/nn842. View

15.

Schlachetzki F, Zhu C, Pardridge W . Expression of the neonatal Fc receptor (FcRn) at the blood-brain barrier. J Neurochem. 2002; 81(1):203-6. DOI: 10.1046/j.1471-4159.2002.00840.x. View

16.

Hardy J, Selkoe D . The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002; 297(5580):353-6. DOI: 10.1126/science.1072994. View

17.

Pan W, Solomon B, Maness L, Kastin A . Antibodies to beta-amyloid decrease the blood-to-brain transfer of beta-amyloid peptide. Exp Biol Med (Maywood). 2002; 227(8):609-15. DOI: 10.1177/153537020222700808. View

18.

Bacskai B, Kajdasz S, McLellan M, Games D, Seubert P, Schenk D . Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci. 2002; 22(18):7873-8. PMC: 6758112. View

19.

Matsuoka Y, Saito M, LaFrancois J, Saito M, Gaynor K, Olm V . Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J Neurosci. 2003; 23(1):29-33. PMC: 6742136. View

20.

Banks W, Terrell B, Farr S, Robinson S, Nonaka N, Morley J . Passage of amyloid beta protein antibody across the blood-brain barrier in a mouse model of Alzheimer's disease. Peptides. 2003; 23(12):2223-6. DOI: 10.1016/s0196-9781(02)00261-9. View